Table 2.
Treatment summary data for recruited participants with wounds subsequently confirmed to be MRSA positive (n = 12)
| Participant | Withdrawal | No. of treatments (frequency) | Microorganisms (in addition to MRSA) * detected at | Wound size (mm2) † measurement at | Adverse events | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yes/No | Week | Reason | Enrolment | Week 4 | Week 12 | Enrolment | Last measure (taken at week no.) [relative to size at enrolment] | |||
| 2 | Yes | 2 | Antibiotics | 8 (daily) | MSSA coliforms | None | nd | 1043 | 1427 (1) [137%] | No |
| 5 | Yes | 6 | Adverse event | 15 (3/week) | None | Citrobacter | nd | 512 | 68 (6) [13%] | Pain |
| 6 | Yes | 1 | Antibiotics | 0 | None | nd | nd | nd | nd | No |
| 8 | Yes | 3 | Death | 7 (3/week) | E. coli Candida sp. | nd | nd | 184 | 160 (1) [87%] | No |
| 10 | Yes | 2 | Hospitalised | 13 (daily) | P. aeruginosa | nd | nd | 2579 | 6383 (1) [247%] | No |
| 12 | Yes | 11 | Antibiotics | 30 (3/week) | None | None | nd | 54 | 62 (11) [115%] | No |
| 14 | Yes | 2 | Antibiotics | 3 (3/week) | None | nd | nd | 55 | 17 (2) [31%] | No |
| 15 | Yes | 8 | Antibiotics | 22 (3/week) | None | None | nd | 60 | 44 (8) [73%] | No |
| 16 | No | – | – | 35 (3/week) | None | None | S. maltophilia anaerobes | 594 | 485 (10) [82%] | Pain |
| 20 | Yes | 6 | Antibiotics | 35 (daily) | S. maltophilia | P. aeruginosa coliforms | nd | 1932 | 1073 (4) [56%] | No |
| 21 | Yes | 8 | Antibiotics | 8 (3/week) | None | None | nd | 3922 | 3447 (8) [88%] | Pain |
| 22 | No | – | – | 33 (3/week) | None | None | Gram‐positive bacilli | 17152 | 9947 (12) [52%] | No |
MRSA, methicillin‐resistant Staphylococcus aureus; MSSA, methicillin‐susceptible S. aureus; nd, not done; AMWIS, advanced medical wound imaging system.
Bold text indicates wounds that reduced in size.
*MRSA was detected on all initial and subsequent swabs.
†AMWIS area data.